Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | UBE2M | P61081 | 2/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.31 |
| ▸ | CCR5 | P51681 | 7/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2251803 | 0.93 | DRD2 (0.33) | GPR119KCNH2UBE2MDCUN1D1CDK1 | |
| SCHEMBL2254899 | 0.93 | CDK1 (0.35) | KCNH2UBE2MDCUN1D1CDK1CDK2 | |
| SCHEMBL2253313 | 0.92 | CCR5 (0.36) | GPR119KCNH2UBE2MDCUN1D1JAK2 | |
| SCHEMBL2249707 | 0.92 | UBE2M (0.32) | KCNH2UBE2MDCUN1D1CDK1CDK2 | |
| SCHEMBL2255297 | 0.92 | DRD2 (0.33) | UBE2MDCUN1D1CDK1CDK2CDK8 | |
| SCHEMBL2251493 | 0.91 | UBE2M (0.36) | GPR119KCNH2UBE2MDCUN1D1CDK1 | |
| SCHEMBL2256057 | 0.89 | UBE2M (0.37) | GPR119KCNH2UBE2MDCUN1D1CDK1 | |
| SCHEMBL2250463 | 0.85 | CCR5 (0.35) | GPR119KCNH2UBE2MDCUN1D1CDK1 | |
| SCHEMBL2250434 | 0.85 | CDK2 (0.36) | KCNH2UBE2MDCUN1D1JAK2JAK1 | |
| SCHEMBL2256106 | 0.85 | CCR5 (0.36) | KCNH2UBE2MDCUN1D1CDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003642-B2 | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | claimed |
| US-8003642-B2 | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20090131403-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1995246-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131403-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | CXCR3, CCR5, HLA-DRB1 | GPR119 243/4885KCNH2 4115/4885UBE2M 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.